Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry wrong stock
i see this is the one that wiped out shs in nov 2016
O/s from 3m to what 30m in 3 months?
Will go to 100m quick
disgusting have fwt!
Brokerage lists the 3m figure now
Shitshow $endv
Flowchart?
Stay away with that bs
$endv
Wtf is right!
Cover page says 3,274,764 o/s
pg 16 says after the subsequent to sept 30 events...ahem!
305,274,746
5.2 m increase in lev3 liabilities
what a mess
10q/a tomorrow is the only sure thing!
Thanks Mann;)
$endv
Wow horrible
turning blockholders into bagholders
$endv
Mann paints the candle green again
That's ok supply and demand
buyers that don't get dilution shares buy it back up
vol is key $endv
Dilute into that!
$endv
Nobody on the screen gets a share then they paint it up so the candle is green
Can set yor watch by mr dump below the bid
$endv
Looking good no big red candles
$endv
Holding 1%
$endv long
I took another 110k
And sold seaheck his shares back in aug
whoopie doo!
$endv @. 0638
Think this will be back at 9 by fri
$endv
Super i wont worry about declaring my supposed 12% then
a/s is 1bthe lmao
Just trade through the supposed o/s today?
Hope i get out of here before finra steps in! Lol
$gthp
Had to take 412 but think it will work out
$gthp
Wow $130m deficit
any sh with less than 80,000 in feb 2016 has 0 shares
time to buy this garbage?
$gthp
$endv reload 700k @ .065
Yes thats why ill pick up an additional 40% @ .06
Along with that other fella you were griping about!
Covered 3800 23s @6.5
See ya $axon!!!
I bot all those high 3s
Resting easier
$endv starter @ .0392
Finished with some 4.44s
$avxl 26,664 @ 4.48
Bring the news
Maybe your watch is wrong?
No fills at 4.38!
Will get before close or moc
today the day?
Curious as to why the claims cite the ratio as 2:5
2mg 2-73 to 5mg don?
Is that not backwards?
Will you be as concerned if Micky Shah leaves?
There is nothing to the don synergy other than tthe rationale to get the compound protected and past the fda regs as superior to soc as jimmy667 said
Again risk vs reward which all are aware as the game is played
I agree wholeheartedly
just as if missling did say more research would be good it means a game is being played
his job is to get the product to market not spend as much $ as needed to fully research the moa
its science + regulations + economics + time
2-73 must be evergreened and combo is the best method
the plus formulation was perbaps based on the degree of inhibition to 2-73s effects as opposed to synergy
Don was simply the best choice of the group to pair with
synergy is gameplay to get protection as seen with the citation for final grant
Obviously the correlation of molecular bioligy to human response is part of the ongoing translational research of phase studies
no one on this board has the answers and when they do it will be too late to act preemptively
i bought with the ceo
You are well aware then i shoul have known
i guess they are working on that presently and we are not privy to the crystal ball
Potency + duration is also important in chronic dosing
almost 2 years since final patient dosing
time for an update!
Hope to see pr for clinical session presentation at cns summit
no sneak peaks this time i guess
Don has much higher affinity for sr1
Don 14nm kato et al., 1999
2-73 860nm maurice et al., 2006
google protein domain and modular conformation to read the tricky parts
Cns diseases summit boston sep 11-12
This is where they presented the p1 data in 2014
Fingers crossed!
The pct app is like a placeholder
the scope of claims may be brief with key trade secrets withheld
look for the national stage entry if it gets published in country
2-73 must be combined for patent protection but others need development
plus could be used with levodopa/carbidopa as control in pk trial since don has been studied for safety with levo
2-73 + valporate in epilepsy and rett appears the route there based upon the aedd presentation
biogen may combo 2-73 with tecfidera in ms
Any discussion on
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017132127&recNum=100&docAn=US2017014702&queryString=(MK2%20or%20MK-2%20or%20MAPKAPK-2%20or%20MAPKAPK2%20or%20mitogen)%20and%20(inhibit%20or%20inhibitor%20or%20modulate%20or%20modulator)&maxRec=160184
I found none but you guys post a lot!
Happy labor day
Anavex assists endoplasmic ptm
http://www.aimspress.com/article/10.3934/biophy.2016.1.27
$avxl
Anavex 2-73 is a pcp analogue
dangerous ground here in the cns
what of it?
$Avxl long
You know you can trust a tie like that!
http://www.polsinelli.com/professionals/tsaunders
$avxl long
Looks to me like a different indication would be game for patent of the mono as novel
Not sure why they did epilepsy precliin as combo
i googled drug evergreen combination
they won't go through p3 to market without best possible protection imo
they are hiding trade secrets in the pct apps
us prov 62/195417 has the info but is not published yet